CCTA Resources

Society-Based Guidelines to support the Use of Coronary CTA

2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain – CCTA has been elevated as the only Class 1 noninvasive test with Level A evidence for diagnosing and guiding treatment decisions. FFRCT (Class 2a) provides information regarding abnormal physiology to guide coronary revascularization decisions in intermediate-to-high risk patients with identified coronary stenoses of 40-90%. Gulati, et al. JACC 2021.

2024 ESC Guidelines for the management of chronic coronary syndromes – CCTA is recommended (Class I) in those with suspected chronic coronary syndrome with low-moderate pretest likelihood of obstructive CAD or if functional imaging is not diagnostic. FFRCT has Class I (>70% proximal LAD) and IIb (intermediate stenosis, proximal or mid coronary) recommendations. Vrints, et al. EHJ 2024.

CAD-RADS™ 2.0 – 2022 Coronary Artery Disease-Reporting and Data System – This expert consensus document updates the 2016 standardized framework for reporting CCTA results according to stenosis, plaque burden, and modifiers. It describes several methods of estimating plaque burden and adds categories P1 to P4 for increasing plaque burden. It adds modifiers for ischemia and exception, and updates the modifier for high-risk plaque. Cury, et al. JCCT 2022.

SCCT 2021 Expert Consensus Document on Coronary Computed Tomographic Angiography – This SCCT consensus statement, the first update since 2009, summarizes current evidence, recommendations, and key questions regarding contemporary use of CCTA. It reviews an extensive body of evidence regarding CCTA and formulates definitive recommendations. Narula, et al. JCCT 2021.

SCCT 2016 Guidelines for the Performance and Acquisition of Coronary Computed Tomographic Angiography – This is a report of the Society of Cardiovascular Computed Tomography Guidelines Committee endorsed by the North American Society of Cardiovascular Imaging (NASCI) to provide standards meant to ensure reliable practice methods and quality outcomes based on the best available data in order to improve the diagnostic care of patients. Abbara, et al. JCCT 2016.

CCTA Acquisition Best Practices

Heart Rate Control and Medication Administration During CCTA

Dr. Jonathon Leipsic, MD, FRCPC, MSCCT, summarizes the rationale and best practices for heart rate control with the use of beta-blockers, and the administration of nitroglycerin for acquiring optimal images during CCTA in accordance with the SCCT guidelines.
25 1104 hf ccta resources heart rate control via beta blocker administration preview image

Heart Rate Control Via Beta-Blocker Administration

25 1104 hf ccta resources nitrate administration during ccta preview image

Nitrate Administration During CCTA

Optimizing CCTA Images for Clinical Practice

Dr. Markus Scherer, MD, FACC, FSCCT, FASE, reviews many factors that can influence CCTA image quality, including: patient selection and preparation, CT Staff expertise, equipment and medication protocols, and image reconstruction.
optimizing ccta images for clinical practice

Heartflow University

Interested in meaningful self-paced educational modules to learn more about best practices for Coronary CTA acquisition?
Heartflow University provides CEUs for CT Technologists and Nurses while learning about optimizing CCTA images and patient management. The catalog of courses also provides access to a broad library of support resources.
CME offerings for physicians are also provided.
Learn More
Starting a Cardiac CT Service?

The Society of Cardiovascular Computed Tomography Starter Kit has tools and resources to operate this service.

Heartflow can partner with you to provide support on coding and reimbursement questions, technology integration, and CT protocols. Learn more on our Reimbursement Resources page.

Partnership Beyond Technology: Heartflow Support

Heartflow provides dedicated regional support specialists to collaborate with your team to enhance and expand your CCTA programs to operate more efficiently and reach more patients.

Disover the CCTA Advantage Today

Learn More

Clinical Evidence That Speaks for Itself

Learn More